stockrowCytek Biosciences, Inc.
CTKB Healthcare Medical Devices
Cytek Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $201.5 million, up 0.52% from fiscal 2024.
- Revenue
- +1.79%
- EPS
- −17.0%
- Free cash flow
- −30.3%
- Total debt
- −84.9%
Quarter to September 2026, against a year earlier
Follow CTKB
Alert me
Cytek Biosciences, Inc. (CTKB) EV/Sales
As of 6 November 2026, Cytek Biosciences, Inc. (CTKB) trades at a EV/Sales of 2.4×. Over the past ten years it has ranged from 0.2× (May 2025) to 20.5× (November 2021); the current reading is higher than 42% of that period. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.9× | (33.06%) |
| FY2024 | 2.8× | (41.46%) |
| FY2023 | 4.9× | (21.73%) |
| FY2022 | 6.2× | (10.43%) |
| FY2021 | 6.9× | 56.62% |
| FY2020 | 4.4× | 0.00% |
| FY2019 | 4.4× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 2.5× | 66.28% |
| Jun 2026 | 1.5× | 2.44% |
| Mar 2026 | 1.5× | (22.77%) |
| Dec 2025 | 1.9× | 106.71% |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| INMD InMode Ltd. compare | 0.8× |
| VREX VAREX IMAGING compare | 1.2× |
| TCMD Tactile Systems Technology, Inc. compare | 1.5× |
| BVS Bioventus Inc. compare | 1.6× |
| CTKB Cytek Biosciences, Inc. | 2.2× |
| KIDS OrthoPediatrics Corp. compare | 3.1× |
| BBNX Beta Bionics, Inc. compare | 3.8× |
| PACB Pacific Biosciences of California, Inc. compare | 7.5× |
| AVR Anteris Technologies Global Corp. compare | 128× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)